This page contains brief information about dasatinib and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
FDA label information for this drug is available at DailyMed.
Use in Cancer
Dasatinib is approved to treat:
- Acute lymphoblastic leukemia that is Philadelphia chromosome positive. It is used:
- In children aged 1 year or older with newly-diagnosed cancer. It is used with other chemotherapy drugs.
- In adults whose disease did not respond to other drugs or who are not able to receive other drugs.
- Chronic myelogenous leukemia (CML) that is Philadelphia chromosome positive. It is used:
- In children aged 1 year or older with chronic phase CML.
- In adults with chronic phase CML that is newly diagnosed.
- In adults with chronic phase, accelerated phase, or blastic phase CML who cannot receive other drugs or whose cancer did not respond to other drugs, including imatinib mesylate.
Dasatinib is also being studied in the treatment of other types of cancer.
More About Dasatinib
Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
MedlinePlus Information on Dasatinib - A lay language summary of important information about this drug that may include the following:
- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.
Research Results and Related Resources
Clinical Trials Accepting Patients
Find Clinical Trials for Dasatinib - Check for trials from NCI's list of cancer clinical trials now accepting patients.